Abstracts tagged "T Cell"

Abstract Number: 0985 • ACR Convergence 2025
Lupus Skin Shapes a Distinct Inflammatory Milieu that Drives the Skewing of Treg and inflammatory T cells
Hiroshi Kato¹, Lin Zhang¹, Mehrnaz Gharaee-Kermani², Amy Hurst¹, Rachael Bogle³, Alex Tsoi³, Johann Gudjonsson² and J. Michelle Kahlenberg², ¹Michigan Medicine, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Holland, OH
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a frequent manifestation of systemic lupus erythematosus (SLE) and remains an important contributor to morbidity in lupus patients. Despite…
Abstract Number: 1482 • ACR Convergence 2025
Evaluation of T Cell Subpopulations, CD4/CD8 Ratio and p16INK4a in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
Erik Cimé-Aké¹, Guadalupe Lima¹, Emilio Godinez-Lazarini¹, Sandra Juárez¹, Hilda Marín-López¹, Amairani Gómez-Rodríguez¹, Daniela Flores-Hernández¹, Ileana Flores-Hernández¹, Diego F. Hernández-Ramírez¹, Luis Llorente¹ and Hilda Fragoso-Loyo², ¹Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico
Background/Purpose: Cognitive impairment (CI) in systemic lupus erythematosus (SLE) may be associated with different T cell subpopulations distribution and chronic pro-inflammatory state in which immunosenescence…
Abstract Number: 2641 • ACR Convergence 2025
Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases
Ricardo Grieshaber-Bouyer¹, Jamie Haddon², Maria Gabriella Raimondo³, Carlo Tur³, Sebastian Böltz³, Tobias Dashi⁴, Melanie Hagen⁵, Andreas Wirsching³, Tobias Rathe⁴, Xuan Wu⁶, Peter Wung², Francis Kim², Yonghong Zhu⁶, Ken Song², Timothy Lu⁷ and Georg Schett⁸, ¹University Hospital Erlangen, Erlangen, Germany, ²Candid Therapeutics, San Diego, CA, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine ³- Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁵Friedrich-Alexander-University Erlangen-Nuremberg, Department of Internal Medicine ³ - Rheumatology and Immunology, Erlangen, Germany, ⁶EpimAb Biotherapeutics, Shanghai, China (People's Republic), ⁷Candid Therapeutics, San Diego, ⁸Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: Emerging data show the potential of T-cell engagers (TCEs) for deep B cell depletion to treat autoimmune diseases. Cizutamig is a purposefully designed BCMAxCD3…
Abstract Number: 0869 • ACR Convergence 2025
PD-1 inhibitor unleashes pathogenic CD8+ T cells and induce arthritis in collagen-primed mice
Clement Adedeji¹, Muhammad Hamdan¹, Hong-Jai Park², Kelsey Wang¹ and Sang Kim³, ¹Yale University, New Haven, ²Yale University, New Haven, CT, ³Yale University, Branford, CT
Background/Purpose: Background/Purpose: Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events, including inflammatory arthritis (ICI-arthritis). The pathophysiology of ICI-arthritis, particularly the role of T…
Abstract Number: 0986 • ACR Convergence 2025
LBL-053, A Novel Anti-TL1A/p40 Bispecific Antibody for the Treatment of Autoimmune Disorders.
Shuijun Hu¹, Fengxia Li¹, Aixia Liu¹, Hailin Wang¹, Xiaoxiao Liu¹, Jianming Sun¹, Yurong Qin¹, Guojin Wu¹, Jing Guan¹, Hui Yuwen¹, Jordan Zhu², Xiaoqiang Kang¹, Xiao Huang¹ and Hong Ling¹, ¹Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Inflammatory bowel disease (IBD) is a chronic, immune-mediated, inflammatory disease of the digestive tract. Several biological agents have greatly improved clinical course, remission, and…
Abstract Number: 1508 • ACR Convergence 2025
Dissecting the Role of T Cell Subsets and Complements in Lupus Pathogenesis in Systemic Lupus Erythematosus Patients with Obesity
Sheila Serin¹, Megan Schluentz¹, Chandana Keshavamurthy¹, Alexandra Reese¹, Sneha Centala¹, Bettina Boone¹, Samantha Ahrens², William Davis³, Robert Quinet¹, Jerald Zakem⁴, Samina Hayat⁵, Sarwat Umer⁶, Teresa leeth⁷, Daniyal Nadeem⁷ and Xin Zhang⁸, ¹Department of Rheumatology, Ochsner Health, New Orleans, LA, ²Multi-specialty Clinical Research, Ochsner Health, New Orleans, LA, ³Ochsner Health System, New Orleans, LA, ⁴Ochsner Health Systems, Metairie, LA, ⁵Louisiana state university Shreveport, Shreveport, LA, ⁶LSUHSC Shreveport, Shreveport, LA, ⁷Louisiana State University Health Science, Shreveport, LA, ⁸Ochsner Medical Center, New Orleans, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation, autoantibody production, and multiorgan involvement. Although genetic, hormonal, and environmental factors…
Abstract Number: 2693 • ACR Convergence 2025
CAR T-cell Therapy in SLE: A Systematic Review
Alberto Nordmann-Gomes¹, Leila Khalili², Wei Tang³, Laura Geraldino-Pardilla⁴, Yevgeniya Gartshteyn⁵, Robert Clancy⁴, Stephen Suh⁶, Maya Souvignier⁶, Michel Sadelain⁶ and Anca Askanase², ¹Columbia University Irving Medical Center, New York, NY, ²Columbia University Medical Center, New York, NY, ³Westchester Medical Center, Valhalla, NY, ⁴Columbia University, New York, NY, ⁵Columbia University Medical Center, Glen Rock, NJ, ⁶Columbia University Irving Medical Center, New York City, NY
Background/Purpose: CAR T-cell therapy is poised to revolutionize the treatment of systemic lupus erythematosus (SLE). Recently, several authors have reported their experience using CAR T-cell…
Abstract Number: L03 • ACR Convergence 2024
CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus
Kyleigh Brimmer¹, Olivia Antao¹, Daniel Mayer¹, Gina Sanchez¹, Rebecca Francis¹, Htay Htay Kyi², Mary Salim², Boyan Xia², Eugenio Capitle² and Jason Weinstein¹, ¹Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, ²Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
Abstract Number: L16 • ACR Convergence 2024
Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial
Megan Clowse¹, David Isenberg², Joan Merrill³, Thomas Dörner⁴, Michelle Petri⁵, Edward Vital⁶, Eric Morand⁷, Teri Jimenez⁸, Stephen Brookes⁹, Janine Gaiha-Rohrbach¹⁰, Christophe Martin¹¹, Annette Nelde¹² and Christian Stach¹³, ¹Division of Rheumatology and Immunology, Duke University, Durham, NC, ²Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁸UCB, Raleigh, NC, ⁹Biogen, Maidenhead, United Kingdom, ¹⁰Biogen, Cambridge, MA, ¹¹UCB, Slough, United Kingdom, ¹²Biogen, Baar, Switzerland, ¹³UCB, Monheim am Rhein, Germany
Background/Purpose: Dapirolizumab pegol (DZP) is a novel, polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment, lacking an Fc domain, that inhibits CD40L signaling. By binding to CD40L,…
Abstract Number: 0003 • ACR Convergence 2024
CLN-978, a CD19-directed T Cell Engager (TCE), Leads to Rapid and Deep B Cell Depletion and Has Broad Potential for Development in Autoimmune Diseases
Máire F. Quigley¹, Jennifer S. Michaelson¹, Jeffrey Jones¹, Farrukh T. Awan², Geoffrey P. Shouse³, Yue Zhang¹, Todd Shearer¹, Judy Inumerable¹, Irina M. Shapiro¹, Patrick A. Baeuerle¹ and Stephen Wax¹, ¹Cullinan Therapeutics, Inc., Cambridge, ²UT Southwestern Medical Center, Dallas, ³City of Hope Comprehensive Cancer Center, Duarte
Background/Purpose: CD19-directed CAR T cell therapy has been reported to induce profound B cell depletion and deep clinical responses, including drug-free remission, in patients with…
Abstract Number: 0499 • ACR Convergence 2024
PD-1hiCXCR5-CD4+T Peripheral Helper Cells Enrich in Rheumatoid Arthritis and Predict Clinical Response to Anti-TNF Treatment
Wanki Ho¹, Huaqun Zhu¹, Hua Ye¹, Dongdong Fu² and Xi Xu¹, ¹Peking University People's Hospital, Beijing, China, ²Xinxiang Central Hospital, Xinxiang, Henan, China (People's Republic)
Background/Purpose: PD-1hiCXCR5-CD4+T peripheral helper cells (Tph) are newly identified pathogenic CD4+T helper cells and participate in rheumatoid arthritis (RA) pathogenesis. However, the clinical significance of…
Abstract Number: 1134 • ACR Convergence 2024
First-in-Human Evaluation of the Safety, Tolerability and Pharmacokinetics of the T Cell Receptor Signal Modulator AX-158
Christopher VanDeusen¹, Andres Gagete¹, Annelize Koch² and D Scott Batty Jr¹, ¹Artax Biopharma, Inc, Cambridge, MA, ²Simbec-Orion, Merthyr Tydfil, Wales, United Kingdom
Background/Purpose: Nck is a cytosolic protein that binds a domain of the T cell receptor (TCR) following TCR interaction to amplify responses from low affinity…
Abstract Number: 1785 • ACR Convergence 2024
Comparative Immuno-Metabolomics Shows Singular Changes in Systemic Lupus Erythematosus Metabolic Phenotype Induced by T-Cell Activation
Martin Stradner¹, Fernanda Monedeiro², Elmar Zuegner², Barbara Prietl³, Monika Oberhuber⁴, Michael Khalil⁵, Christoph Magnes², Hans-Peter Brezinsek¹, Angela Libiseller³ and Thomas Pieber³, ¹Div. of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ²Joanneum Research, Graz, Austria, ³Div. of Endocrinology, Medical University of Graz, Graz, Austria, ⁴CBmed, Graz, Austria, ⁵Dept. of Neurology, Medical University of Graz, Graz, Austria
Background/Purpose: Metabolic processes have a critical role in regulating immune cell function, therefore being relevant to understanding the pathogenesis and progression of autoimmune diseases. Here…
Abstract Number: 1850 • ACR Convergence 2024
Exhausted T-cells Are Increased in Autoimmune Diseases and Predict Response to Anti-TNF in RA and SPA Patients
Samuel Bitoun¹, Marie Naigeon², Matthieu Roulleaux- Dugage², Caroline De Oliveira², Caroline Berthot², Xavier Mariette³, Gaetane Nocturne³ and Nathalie Chaput-Gras², ¹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, ²Laboratoire d'immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy,, Villejuif, France, ³Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France
Background/Purpose: Exhaustion can occur after prolonged activation of T cells limiting their immunosurveillance function leading to cancer emergence. Among the exhaustion markers expressed on T…
Abstract Number: 1988 • ACR Convergence 2024
A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
Marta Cossu¹, Carolina Bobadilla Mendez², Amanda Jackson³, Eugene Myshkin⁴, Grace Liu⁵, Edwin Lam⁶, Ulf H. Beier², Kathleen Weisel², Brittney Scott², Jocelyn H. Leu⁶, Sheng Gao² and Dessislava Dimitrova², ¹Janssen Pharmaceutical Research and Development, a Johnson & Johnson company, Leiden, Netherlands, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, ³Janssen Research & Development, LLC, La Jolla, CA, ⁴Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, ⁵Janssen Research & Development, LLC, a Johnson & Johnson company, Raritan, NJ, ⁶Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA
Background/Purpose: Nipocalimab is a human IgG1 monoclonal antibody targeting the neonatal Fc receptor (FcRn) that selectively reduces IgG levels without impacting antigen presentation, T- and…

« Previous Page
1
…
3
4
5
6
7
…
26
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].